Zevalin (CD20-targeted 90Yttrium-ibritumomab tiuxetan), Bexxar (CD20-targeted iodine-131 tositumomab), Ontak (CD25-targeted diphtheria toxin-IL-2 fusion protein), and Mylotarg (CD33-targetd gemtuzumab oxogamicin) have been successfully used for non-Hodgkin's lymphoma, T-cell lymphoma, and acute myeloid leukemia. The gene discussed is CD33; the disease is acute myeloid leukemia.